YOLFTbeta
23

Jw Life Science Corp

234080 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

10,610.00KRW+40.00 (+0.38%)

Price History

Full chart

Market Stats

Previous Close10,570.00
Open10,610.00
Day Range10,580.00 – 10,730.00
52-Week Range10,550.00 – 14,932.79
Volume8.16K
Market Cap170.79B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield4.97%
Beta0.24
50-Day Avg11,167.40
200-Day Avg12,159.70

About

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOSungnam Cha
  • Employees297
  • Headquarters28, Hanjin 1-gil, Dangjin-si, South Korea, 31720, Korea
  • Websitehttps://www.jw-lifescience.co.kr

Leadership

  • Sungnam ChaCEO & Director
  • Jeong Yeol NohExecutive Director & Head of HP Research Center
  • Na Sook HeeExecutive Director

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue125.95B132.29B143.60B155.23B170.22B183.52B169.82B188.93B206.86B222.48B257.83B
Growth (%)-+5.03%+8.55%+8.10%+9.66%+7.81%-7.47%+11.26%+9.49%+7.55%+15.89%
Cost of Revenue95.81B98.01B106.42B115.72B121.62B124.02B120.66B140.81B154.47B164.97B185.51B
Gross Profit30.14B34.28B37.18B39.51B48.60B59.50B49.16B48.12B52.39B57.51B72.32B
Gross Margin23.93%25.91%25.89%25.46%28.55%32.42%28.95%25.47%25.33%25.85%28.05%
Operating Expense11.48B12.65B13.40B15.97B18.86B20.05B20.74B21.03B21.53B21.65B39.07B
Operating Income18.66B21.63B23.78B23.54B29.75B39.45B28.42B27.09B30.86B35.86B33.24B
Operating Margin14.81%16.35%16.56%15.17%17.48%21.50%16.73%14.34%14.92%16.12%12.89%
EBITDA--34.97B34.67B41.68B36.04B32.81B38.83B51.93B76.82B52.78B
EBITDA Margin--24.35%22.33%24.49%19.64%19.32%20.55%25.10%34.53%20.47%
Net Income12.86B15.16B16.78B15.82B21.94B16.87B12.91B14.96B28.14B43.99B28.61B
Net Income Margin10.21%11.46%11.69%10.19%12.89%9.19%7.60%7.92%13.61%19.77%11.09%
R&D398.98M664.66M399.42M1.25B3.58B5.20B6.24B5.74B5.16B4.03B5.55B
R&D as % of Total Revenue0.32%0.50%0.28%0.80%2.10%2.83%3.68%3.04%2.49%1.81%2.15%
Interest Expense0002.26B1.73B2.61B1.28B3.09B2.69B2.06B2.84B
Interest Expense % of Total Revenue0.00%0.00%0.00%1.46%1.01%1.42%0.75%1.64%1.30%0.93%1.10%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets179.88B192.24B198.53B200.86B201.40B218.04B219.47B252.94B255.84B325.32B318.21B
Total Liabilities97.05B101.94B96.43B91.60B78.79B85.98B87.97B112.61B96.44B124.88B97.63B
Total Equity82.83B90.30B102.10B109.26B122.62B132.06B131.49B140.33B159.39B200.44B220.58B
Cash864.55M384.56M300.58M12.78B9.86B2.59B4.92B3.92B20.22B7.51B8.38B
Net Debt--60.08B42.25B34.61B33.74B41.37B63.10B26.00B60.20B40.56B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow25.90B16.08B22.05B36.13B24.28B46.75B30.17B14.13B37.57B50.69B40.54B
Investing Cash Flow-24.66B-11.28B-9.03B-10.39B-8.37B-37.56B-22.81B----
Financing Cash Flow-440.27M-5.28B-13.11B-13.27B-18.82B-16.46B-5.03B----
Capital Expenditure23.14B13.37B8.77B10.04B8.09B15.93B18.98B8.29B8.27B10.31B13.43B
Free Cash Flow--13.20B25.57B15.92B30.52B10.77B5.84B29.31B40.38B27.10B
Dividends Paid6.11B6.40B4.75B7.92B7.92B7.92B7.92B7.74B7.74B7.74B7.74B
FCF to OCF--59.88%70.77%65.58%65.27%35.70%41.30%78.00%79.67%66.86%
Dividend Paid to FCF--35.98%30.96%49.73%25.94%73.52%132.68%26.42%19.17%28.57%

Earnings

Report DateMar 31, 2017May 15, 2017Aug 14, 2017Nov 14, 2017Feb 6, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 12, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Feb 12, 2020May 7, 2020Aug 14, 2020Nov 5, 2020Mar 25, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Feb 8, 2022Mar 31, 2022Aug 16, 2022Nov 9, 2022Feb 9, 2023May 15, 2023Aug 10, 2023Nov 9, 2023Jan 30, 2024May 9, 2024Aug 2, 2024Nov 6, 2024Feb 5, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------328.00397.00--331.00----------------------
EPS Actual189.12301.13957.50285.79195.57188.31194.00329.59287.00370.00369.00322.08323.00438.00500.00504.18-405.00366.00331.00270.00-145.42297.40189.00182.00295.42494.75365.80294.11662.90331.49429.91436.691642.65394.42722.01314.24416.72431.84517.56
Surprise-------------1.52%10.33%---222.36%----------------------
TimingAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market-----

Key Statistics & Ratios

Market Cap170.79B
Enterprise Value190.31B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.67
Price / Book0.75
Revenue (TTM)253.71B
Gross Profit (TTM)71.58B
EBITDA51.81B
Profit Margin10.26%
Operating Margin14.78%
Return on Equity11.92%
Return on Assets6.74%
Shares Outstanding15.48M
Shares Float8.56M
Beta0.24
Dividend Yield4.97%
Dividend Rate550.00
Payout Ratio32.73%

Dividends

20261×
550.00Mar 31, 2026
20241×
500.00Dec 27, 2024
20231×
500.00Dec 27, 2023
20221×
500.00Dec 28, 2022
20211×
500.00Dec 29, 2021
20201×
500.00Dec 29, 2020
20191×
500.00Dec 27, 2019
20181×
500.00Dec 27, 2018
20171×
500.00Dec 27, 2017
20161×
300.00Dec 28, 2016

Stock Splits

  • Apr 25, 20182:1